Market Research Reports and Industry Reports

Diabetes, Metabolic Syndrome and Cardiovascular Disease

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimers disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

 1. Overview 11
 1.1 Statement of Report 11
 1.2 About this Report 11
 1.3 Scope of the Report 12
 1.4 Methodology 12
 1.5 Executive Summary 14
 
 2. Introduction 18
 2.1 Demographics of Diabetes 19
 2.1.1 Worldwide Diabetes 19
 2.1.2 U.S. Diabetes 22
 2.2 Economics of Diabetes 27
 2.2.1 Worldwide Costs of Diabetes 27
 2.2.2 Costs of Diabetes in the U.S. 28
 
 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 33
 3.1 Pre-Diabetes Syndrome 34
 3.2 Metabolic Syndrome 34
 3.2.1 Prevalence of Metabolic Syndrome 37
 3.2.2 Management of Metabolic Syndrome 38
 3.2.3 The Outlook for Metabolic Syndrome 38
 3.2.4 The Debate Regarding Metabolic Syndrome 38
 3.3 Diabetes and Inflammation 40
 3.4 Diagnosis of Diabetes Mellitus 41
 3.5 Progression of Diabetes 41
 3.6 Risk Factors and Diabetes 41
 3.6.1 Obesity 43
 3.6.2 Stress-Induced Hyperglycemia 45
 3.7 Complications and Co-Morbidities in Type 2 Diabetes 46
 3.7.1 Preventing Complications and Co-Morbidities in Diabetes 50
 3.7.2 Hypoglycemia Resulting from Treatment 52
 3.8 Cardiovascular Disease (CVD) 52
 3.8.1 CVD Facts 52
 3.8.2 Cardiac Care Therapeutics 59
 3.8.2.1 Anti-Hypertensive Drugs 61
 3.8.2.2 Cholesterol Management Drugs 62
 3.8.2.3 Anticoagulants 66
 3.8.3 CVD Diagnostics 66
 
 4. Pharmaceutical Industry and the Anti-Diabetes Market 68
 4.1 The Worldwide Pharmaceutical Industry 68
 4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 68
 4.1.2 Global Pharmaceutical Market 70
 4.2 Total Diabetes Drug Market Size and Growth 76
 4.2.1 Sales Forecast for the Global Anti-Diabetes Drug Market 80
 4.3 Diabetic Medications Overview 82
 4.3.1 Recent Trends in Diabetic Drug Usage 84
 4.3.2 Market Influence Factors 86
 
 5. Non-Insulin Anti-Diabetes Products 88
 5.1 Anti-Diabetic Drug Therapy Overview 88
 5.1.1 Sulfonylureas 91
 5.1.2 Meglitinides 92
 5.1.3 Biguanides 93
 5.1.4 Thiazolidinediones (TZDs) 94
 5.1.5 α-Glucosidase Inhibitors 96
 5.1.6 Amylin Analog 97
 5.1.7 Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics 97
 5.1.7.1 Byetta (Exenatide) 98
 5.1.7.2 Bydureon (Exenatide LAR) 99
 5.1.7.3 Victoza (Liraglutide) 99
 5.1.7.4 Tanzeum (Albiglutide) 99
 5.1.7.5 Trulicity (Dulaglutide) 100
 5.1.8 DPP-IV Inhibitors 100
 5.1.8.1 Januvia (Sitagliptin) 101
 5.1.8.2 Onglyza (Saxagliptin) 102
 5.1.8.3 Tradjenta (Linagliptin) 102
 5.1.8.4 Galvus (Vildagliptin) 102
 5.1.8.5 Nesina (Alogliptin) 102
 5.1.9 SGLT-2 Inhibitors 103
 5.1.9.1 Invokana (Canagliflozin) 104
 5.1.9.2 Farxiga (Dapagliflozin) 104
 5.1.9.3 Jardiance (Empagliflozin) 105
 5.1.9.4 Suglat (Ipragliflozin) 105
 5.1.9.5 Lusefi (Luseogliflozin) 105
 5.1.10 Combination Therapy 106
 5.1.10.1 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce 107
 5.1.11 Comparisons of the Anti-Diabetes Drugs 107
 5.2 Market Drivers and Trends 107
 5.2.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs 108
 5.3 Non-Insulin Anti-Diabetes Products in the Pipeline 110
 5.3.1 Novel GLP-1 Agonists and Analogs 110
 5.3.2 Novel DPP-IV Inhibitors 113
 5.3.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors 114
 5.3.4 Emerging Anti-Diabetes Targets and Drugs in the Pipeline 115
 5.3.4.1 Novel Approaches to Finding New Drug Targets 119
 
 6. Insulin 120
 6.1 Insulin Markets 120
 6.1.1 Major Players and Market Share 122
 6.1.2 Patent Expirations 124
 6.1.3 Pathway for Insulin Biosimilars 124
 6.1.3.1 Regulatory Avenues for Biosimilar Approval 124
 6.1.3.2 Lantus Biosimilars 125
 6.1.3.3 Key Issues for Insulin Biosimilars 125
 6.1.4 Innovation Strategies 126
 6.2 Insulin Therapeutics 126
 6.2.1 Recommendations for Insulin Initiation and Administration 127
 6.2.2 Short-Acting Insulin 130
 6.2.3 Rapid-Acting Insulin 131
 6.2.3.1 Fast-Acting Insulins in Development 132
 6.2.4 Intermediate-Acting Insulin 133
 6.2.5 Long-Acting Insulin 133
 6.2.6 Insulin Mixtures 134
 6.3 Pipeline Insulins in Development 135
 6.3.1 Tresiba (Novo Nordisk) 135
 6.3.2 Ryzodeg (Novo Nordisk) 135
 6.3.3 Toujeo (Sanofi) 135
 6.3.4 BIOD-531 (Biodel) 135
 6.3.5 Xultophy (Novo Nordisk) 136
 6.3.6 LixiLan (Sanofi) 136
 6.3.7 rHUPH20 and Insulin (Halozyme) 136
 6.3.8 FIAsp (Novo Nordisk) 136
 6.3.9 BIOD-238, BIOD-250, and BIOD-351 (Biodel) 136
 6.3.10 InsuPatch and InsuPad (Insuline Medical) 137
 6.4 Non-Invasive Insulin Delivery 138
 6.4.1 Inhaled Insulin 139
 6.4.1.1 Afrezza 139
 6.4.1.2 Dance Pharmaceuticals and Aerogen (Dance-501) 140
 6.4.1.3 A Chronicle of Inhaled Insulins 141
 6.4.2 Oral Insulin 142
 6.4.3 Transdermal Insulin 145
 6.5 Barriers for Non-Injected Insulin 146
 6.6 Patient Potential for Non-Injected Insulin 147
 6.7 Insulin Delivery Devices 147
 6.7.1 Insulin Pens 149
 6.7.2 Injections Aids 153
 6.7.2.1 Automatic Injectors 154
 6.7.2.2 Syringe Magnifiers 154
 6.7.2.3 Injection Ports 155
 6.7.3 Insulin Jet Injectors 155
 6.7.4 Insulin Pumps 156
 6.7.4.1 External Insulin Pumps 157
 6.7.4.2 OneTouch Ping 159
 6.7.4.3 Accu-Chek Combo Insulin Pump System 160
 6.7.4.4 MiniMed Paradigm Real-Time Revel 160
 6.7.4.5 MiniMed 530G with Enlite 161
 6.7.4.6 Insulet Omnipod 161
 6.7.4.7 DANA IIS 162
 6.7.4.8 t:slim (Tandem Diabetes Care) 162
 6.7.4.9 Snap (Asante) 162
 6.7.4.10 Animas Vibe Pump/CGM 163
 6.7.5 Insulin Infusion Sets 163
 6.7.6 Insulin Patch Pumps in Development or Only Available Outside the U.S. 163
 6.7.7 Implantable Insulin Pumps 166
 6.7.8 Insulin Pump Market Share 166
 6.7.9 Drivers of Demand for Pumps 168
 6.8 Market Forecasts for Insulin Administration Technologies 168
 
 7. Emerging Anti-Diabetes Technologies and Products 169
 7.1 Projections for the Anti-Diabetes Drug Market 169
 7.2 Artificial Pancreas 172
 7.2.1 MiniMed 530G System 173
 7.2.2 Animas Vibe System 174
 7.2.3 Next Generation Medtronic Artificial Pancreas Systems 174
 7.2.4 FDA’s Artificial Pancreas Guidance Document 174
 7.3 Insulin-Producing Cells 174
 7.3.1 Gene Therapy 175
 7.3.2 Cell Therapy Companies for Diabetes 176
 7.3.2.1 ViaCyte (formerly Novocell, Inc.) 176
 7.3.2.2 Sernova 177
 7.4 Pancreatic Transplantation 177
 7.4.1 Candidates for Pancreatic Transplantation 178
 7.4.1.1 Pancreatic Organ Transplantation 178
 7.4.1.2 Allo-Islet Transplantation 179
 7.4.1.3 Implantation of Genetically Engineered b-Cells or Embryonic Stem Cells 179
 7.4.2 ADA Position on Pancreatic Transplantation 179
 7.5 Immune Modulators 180
 7.6 Gastric Bypass Surgery to Treat Type 2 Diabetes 181
 7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 181
 7.7.1 Xenical (Roche) 181
 7.7.2 Qsymia (Vivus) 181
 7.7.3 Belviq (Arena Pharmaceuticals) 182
 7.7.4 Contrave (Orexigen Therapeutics) 182
 7.7.5 Anti-Obesity Drugs in Development 182
 7.8 Other Anti-Diabetic Therapy Drug Candidates 182
 7.8.1 Lipid Abnormalities 182
 7.8.1.1 New Cholesterol Guidelines 183
 7.8.2 High Blood Pressure 185
 7.8.3 Aspirin Therapy 187
 7.9 Drugs Used “Off-Label” 187
 7.9.1 Warfarin Sodium 187
 7.10 Insulin and Anti-Diabetes Drug Combinations 187
 7.10.1 Xultophy (Novo Nordisk) 187
 7.10.2 LixiLan (Sanofi) 188
 
 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 189
 8.1 Diagnostic Guidelines 189
 8.2 Diagnosis of Diabetes 189
 8.2.1 Fasting Plasma Glucose (FPG) Test 192
 8.2.2 Glucose Tolerance Test 193
 8.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c) 193
 8.2.4 Fructosamine 194
 8.2.5 Screening Tests for Diabetes-Related Complications 195
 8.3 Glucose Monitoring 196
 8.3.1 Overview of Market Segment 198
 8.3.2 Competitive Strategies 198
 8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix 200
 8.3.3.1 First-Generation Monitors 201
 8.3.3.2 Second-Generation Monitors 201
 8.3.3.3 Third-Generation SMBG Technologies 202
 8.3.3.4 Product Overview 202
 8.3.3.4.1 LifeScan, Inc. 202
 8.3.3.4.2 Roche Diagnostics 205
 8.3.3.4.3 Bayer HealthCare 206
 8.3.3.4.4 Abbott Diabetes Care 208
 8.3.3.4.5 Other Players 210
 8.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device? 211
 8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development 212
 8.3.6 Future of Non-Invasive Glucose Technology 212
 8.3.7 Lancets and Lancing Devices 212
 
 9. Market Trends, Challenges and Strategic Options 216
 9.1 Overview 216
 9.2 Diabetes Drug Market Trends 216
 9.2.1 Overview 216
 9.2.2 Emergence of Therapeutics with Improved Administration Characteristics 216
 9.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics 218
 9.2.3 Increasing Prevalence of Obesity 218
 9.2.4 Consumer Preference Drives Product Development in Invasive Technology Segment 219
 9.3 Diabetes Mellitus Market Challenges 219
 9.3.1 Overview 219
 9.3.2 Patent Expirations 220
 9.3.3 Market Prospects of Inhalable Insulin 220
 9.4 Strategic Options 221
 9.4.1 Developing Countries are Key Markets for Growth 222
 9.4.2 Consumer-Driven Marketing Campaigns 223
 9.4.3 Strategies for Successful New Product Launches 223
 9.4.4 Collaborations and Strategic Alliances 224
 9.5 FDA Guidelines for Developing Anti-Diabetic Drugs 224
 9.6 Recent Industry Activity 225
 
 10. Company Profiles 228
 10.1 A. Menarini 228
 10.2 Abbott Laboratories 228
 10.3 Abbvie 232
 10.4 Amgen 232
 10.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) 233
 10.6 Animas (part of Johnson & Johnson) 233
 10.7 Asante 233
 10.8 Astellas Pharma, Inc. 233
 10.9 AstraZeneca Plc 234
 10.10 Bayer 235
 10.11 Becton, Dickinson and Company 237
 10.12 Biocon 238
 10.13 Biodel 239
 10.14 BodyMedia 239
 10.15 Boehringer Ingelheim 239
 10.16 Bristol Myers Squibb 240
 10.17 Cellnovo 240
 10.18 CeQur 240
 10.19 ConjuChem 240
 10.20 Daiichi Sankyo 241
 10.21 Dance Biopharm 241
 10.22 Debiotech 241
 10.23 DexCom 241
 10.24 Echo Therapeutics, Inc. 243
 10.25 Eli Lilly 244
 10.26 FIFTY50 Medical, Inc. 245
 10.27 Flamel Technologies 245
 10.28 Generex Biotechnology Corporation 245
 10.29 GlaxoSmithKline Plc 245
 10.30 Halozyme Therapeutics 246
 10.31 Insulet 246
 10.32 Insuline Medical Ltd. 247
 10.33 Intarcia Therapeutics, Inc. 247
 10.34 Janssen Research & Development 247
 10.35 Johnson & Johnson 248
 10.36 Kowa Pharmaceuticals 249
 10.37 Lexicon Pharmaceuticals 249
 10.38 MannKind Corporation 250
 10.39 Medipacs 250
 10.40 Medtronic 250
 10.41 Merck & Company, Inc. 251
 10.42 Mitsubishi Tanabe Pharma Corporation 252
 10.43 Novartis 252
 10.44 Novo Nordisk 252
 10.45 Oramed Pharmaceuticals 253
 10.46 Orexigen Therapeutics, Inc. 253
 10.47 Owen Mumford 254
 10.48 PhaseBio Pharmaceuticals 254
 10.49 Pfizer 254
 10.50 Prometheon Pharma 255
 10.51 Roche Diagnostics 255
 10.52 Sanofi-Aventis 257
 10.53 Sernova 258
 10.54 Smiths Medical 258
 10.55 SOOIL Development 259
 10.56 Taisho Pharmaceuticals 259
 10.57 Takeda 259
 10.58 Tandem Diabetes Care, Inc. 259
 10.59 Theracos, Inc. 260
 10.60 Transdermal Specialties, Inc. 260
 10.61 TransTech Pharma 260
 10.62 Valeritas 260
 10.63 Viacyte, Inc. (formerly Novocell) 261
 10.64 Vivus, Inc. 261
 10.65 Ypsomed Holding 261
 10.66 Zealand Pharma A/S 261


List Of Tables

 Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035 20
 Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20-79 Years Age Group),
 2013 and 2035 21
 Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013 21
 Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013 22
 Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013 24
 Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010 25
 Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012 29
 Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009 30
 Table 2.9: Healthcare Utilization by Diabetic Patients, 2012 31
 Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome 35
 Table 3.2: Ethnic Specific Values for Waist Circumference in IDF’s Metabolic Syndrome Criteria 35
 Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome 35
 Table 3.4: Additional Metabolic Criteria for Research 37
 Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 46
 Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes 48
 Table 3.7: Prevalence of Complications Among Patients with Diabetes 49
 Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus 49
 Table 3.9: Major Causes of End-Stage Renal Disease 49
 Table 3.10: Clinical Recommendations for Adults with Diabetes 51
 Table 3.11: Laboratory Assessment of Diabetic Vascular Disease 51
 Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management 52
 Table 3.13: Summary of Cardiovascular Diseases (CVDs) 52
 Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008 54
 Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S.,
 2010 58
 Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016 60
 Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017 61
 Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014 68
 Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2013 68
 Table 4.3: Leading Therapy Classes for R&D, 2014 69
 Table 4.4: Leading Disease Indications for R&D, 2014 70
 Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012 70
 Table 4.6: Global Pharmaceutical Sales by Region and Country, 2012 and 2017, and CAGR 2008-2012 and
 2013-2017 71
 Table 4.7: World Pharmaceutical Sales Share by Region, 2012 72
 Table 4.8: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013 73
 Table 4.9: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2009-2013 73
 Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2017 73
 Table 4.11: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2017 74
 Table 4.12: Top Selling Drugs in the U.S., 2013 74
 Table 4.13: Top Selling Drugs Worldwide, 2013 75
 Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2013 75
 Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018 76
 Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018 76
 Table 4.17: Anti-diabetic Therapy Markets, 2013 77
 Table 4.18: The Leading Five Anti-Diabetics by Global Sales, 2013 80
 Table 4.19: The Leading Five Anti-Diabetics by U.S. Sales, 2013 80
 Table 4.20: Top Five Branded Anti-Diabetics by Prescription in the U.S., 2013 80
 Table 4.21: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes 82
 Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy 83
 Table 5.1: Classes of Non-Insulin Hypoglycemic Agents 89
 Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014 90
 Table 5.3: Relative Efficacy of Diabetes Drugs 91
 Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations 106
 Table 5.5: Worldwide Anti-Diabetes Non-Insulin Drug Market, 2010-2018 109
 Table 5.6: U.S. Anti-Diabetes Non-Insulin Drug Market, 2010-2018 109
 Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development 110
 Table 5.8: DPP-IV Inhibitor Pipeline: Selected Drugs in Development 113
 Table 5.9: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development 115
 Table 5.10: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development 115
 Table 5.11: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories 116
 Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2013 120
 Table 6.2: Worldwide Insulin Market, 2010-2018 121
 Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2013 121
 Table 6.4: U.S. Insulin Market, 2010-2018 121
 Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2013 122
 Table 6.6: Worldwide Insulin Sales and Value Market Share by Company, 2013 122
 Table 6.7: U.S. Insulin Sales and Value Market Share by Company, 2013 123
 Table 6.8: Insulins on the U.S. Market 126
 Table 6.9: Pharmacokinetics of Therapeutic Insulins on the U.S. Market 128
 Table 6.10: Comparison of Recommendations from Existing Guidelines 130
 Table 6.11: Pharmacokinetics of Short-Acting Insulins 130
 Table 6.12: Pharmacokinetics of Rapid-Acting Insulins 131
 Table 6.13: Pharmacokinetics of Intermediate-Acting Insulins 133
 Table 6.14: Pharmacokinetics of Long-Acting Insulins 133
 Table 6.15: Pharmacokinetics of Insulin Mixtures 134
 Table 6.16: A Comparison of Existing Insulin Delivery Devices 148
 Table 6.17: Insulin Pens 150
 Table 6.18: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018 152
 Table 6.19: Injection Aids 153
 Table 6.20: Jet Injectors 155
 Table 6.21: Control Averages by Treatment 156
 Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal 157
 Table 6.23: Leading Insulin Pump Manufacturers 157
 Table 6.24: Comparison of Current External Insulin Pumps on the Market 158
 Table 6.25: Insulin Infusion Sets 163
 Table 6.26: Worldwide Insulin Pump Market, 2013-2018 167
 Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies 172
 Table 7.2: Cells of the Pancreas 175
 Table 7.3: Statin Recommendations for Designated Treatment Groups 183
 Table 7.4: Statins Currently Available in the U.S. 184
 Table 7.5: Statin Intensity Chart 184
 Table 7.6: Summary of Non-Statin Cholesterol Lowering Drugs 185
 Table 7.7: Suggested Pharmacological Treatment Agents for Hypertension 186
 Table 8.1: Criteria for the Diagnosis of Diabetes 190
 Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes) 190
 Table 8.3: Normal Glucose Values—Fasting State 190
 Table 8.4: Criteria for Testing for Diabetes in Asymptomatic Adults 191
 Table 8.5: Criteria for Type 2 Diabetes in Asymptomatic Children 191
 Table 8.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM) 192
 Table 8.7: Laboratory Assessment of Diabetic Vascular Disease 196
 Table 8.8: Worldwide Glucose Self-Testing Market Sales (includes Meters, Strips and Lancets),
 2012-2018 197
 Table 8.9: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2012-2018 197
 Table 8.10: Market Share of U.S. Blood Glucose Self-Testing, 2013 198
 Table 8.11: Lancet Characteristics 215
 Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2013 222
 Table A1.1: Select Archived Press Release Excerpts 266


List Of Figures

 Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035 19
 Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013 20
 Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years,
 1980-2012 23
 Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012 24
 Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013 24
 Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010 26
 Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010 27
 Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD),
 2013 28
 Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012 30
 Figure 2.10: Percent of Medical Condition-Specific Expenditures Associated with Diabetes, 2012 31
 Figure 3.1: Maintenance of Normal Blood Sugar Levels 33
 Figure 3.2: Prevalence of Self-Reported Obesity (BMI ³30) Among U.S. Adults, 2012 43
 Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010 44
 Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010 44
 Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010 45
 Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011 46
 Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011 50
 Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011 50
 Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009 54
 Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009 55
 Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular Disease in the U.S., 2010 55
 Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010 56
 Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010 57
 Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010 58
 Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2007-2012 63
 Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2010-2018 81
 Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2010-2018 82
 Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012 83
 Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2013 85
 Figure 5.1: Overview of GLP-1 and Blood Glucose 97
 Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose 101
 Figure 5.3: SGLT-2 Inhibitor Mechanism of Action 103
 Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2013 108
 Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2013 108
 Figure 6.1: Global Sales of Lantus, 2005-2013 123
 Figure 6.2: Insulin Pump Market Share, 2013 167


Neighborhood Diabetes, Inc Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Neighborhood Diabetes, Inc Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

2016-2021 Emerging US Home/Self Testing Diagnostics Market: Diabetes, Pregnancy, Ovulation, Occult Blood -- Business Challenges and Marketing Strategies for Suppliers

This new 175-page report from VPGMarketResearch.com provides analysis of the major home/self testing market segments, including diabetes (strips and meters), pregnancy, ovulation, and occult blood.  The report presents trends, dynamics, size,

USD 1450View Report

Thermalin Diabetes, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Thermalin Diabetes, LLC (Thermalin) is a biotechnology company that manufactures and develops insulin analogs. The company is developing ultra-concentrated insulin analog for the treatment of individuals with high insulin resistance

USD 250View Report

Global Metabolic Syndrome Consumption 2016 Market Research Report

The Global Metabolic Syndrome Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Metabolic Syndrome market.First, the report provides a basic overview

USD 4000View Report

Global Metabolic Syndrome Industry 2016 Market Research Report

The Global Metabolic Syndrome Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Metabolic Syndrome industry.Firstly, the report provides a basic overview

USD 2800View Report

Metabolic Syndrome-Pipeline Insights, 2016

SUMMARYDelveInsights, Menopausal Hot Flashes-Pipeline Insights, 2016, report provides in depth insights on the pipeline drugs and their development activities around the Menopausal Hot Flashes. The DelveInsightsReport covers the product

USD 1250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 5500
  • 10 User Licence    $ 11000
  • Enterprise Wide Licence    $ 16500
$ 5500

Reports Details

Published Date : Jan 2016
No. of Pages :270
Country :Global
Category :Healthcare
Publisher :TriMark Publications, LLC
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment